{
    "pmcid": "8458290",
    "qa_pairs": {
        "What effect does the binding of nanobody C5 have on the spike protein conformation?": [
            "Induces an all-down conformation, rendering it inactive",
            "Induces an all-up conformation, enhancing ACE2 interaction",
            "Causes partial unfolding of the spike protein",
            "Stabilizes the spike protein in its active form"
        ],
        "What is the primary target of the nanobodies developed in the study for neutralizing SARS-CoV-2?": [
            "The receptor-binding domain (RBD) of the spike protein",
            "The nucleocapsid protein of the virus",
            "The membrane protein of the virus",
            "The RNA polymerase of the virus"
        ],
        "What was the observed therapeutic efficacy of the C5-trimer in the Syrian hamster model?": [
            "It demonstrated potent therapeutic efficacy both as a treatment and prophylactic agent",
            "It showed limited efficacy only as a prophylactic agent",
            "It was ineffective as both a treatment and prophylactic agent",
            "It demonstrated efficacy only when combined with other antiviral drugs"
        ],
        "Which SARS-CoV-2 variant showed reduced binding affinity for nanobodies C5 and H3 due to mutations?": [
            "Beta (B.1.351)",
            "Alpha (B.1.1.7)",
            "Gamma (P.1)",
            "Delta (B.1.617.2)"
        ],
        "Which nanobodies were found to bind to an epitope overlapping with the ACE2 binding site?": [
            "C5 and H3",
            "C1 and F2",
            "C5 and F2",
            "H3 and C1"
        ]
    }
}